IL177268A0 - Site -specific chemical modification of hiv gp41-derived peptides - Google Patents

Site -specific chemical modification of hiv gp41-derived peptides

Info

Publication number
IL177268A0
IL177268A0 IL177268A IL17726806A IL177268A0 IL 177268 A0 IL177268 A0 IL 177268A0 IL 177268 A IL177268 A IL 177268A IL 17726806 A IL17726806 A IL 17726806A IL 177268 A0 IL177268 A0 IL 177268A0
Authority
IL
Israel
Prior art keywords
hiv
site
chemical modification
specific chemical
derived peptides
Prior art date
Application number
IL177268A
Other languages
English (en)
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of IL177268A0 publication Critical patent/IL177268A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL177268A 2004-03-15 2006-08-03 Site -specific chemical modification of hiv gp41-derived peptides IL177268A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55306304P 2004-03-15 2004-03-15
PCT/US2005/007486 WO2005089796A1 (en) 2004-03-15 2005-03-08 Site-specific chemical modification of hiv gp41-derived peptides

Publications (1)

Publication Number Publication Date
IL177268A0 true IL177268A0 (en) 2006-12-10

Family

ID=34993445

Family Applications (1)

Application Number Title Priority Date Filing Date
IL177268A IL177268A0 (en) 2004-03-15 2006-08-03 Site -specific chemical modification of hiv gp41-derived peptides

Country Status (6)

Country Link
EP (1) EP1734994A1 (ja)
JP (1) JP2007529522A (ja)
CN (1) CN1929860A (ja)
CA (1) CA2556032A1 (ja)
IL (1) IL177268A0 (ja)
WO (1) WO2005089796A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725262B1 (en) 2004-03-15 2021-05-26 Nektar Therapeutics Polymer-based compositions and conjugates of hiv entry inhibitors
WO2007056083A2 (en) * 2005-11-02 2007-05-18 Ambrx, Inc. Biosynthetic polypeptide fusion inhibitors
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CA2651793C (en) * 2006-02-02 2015-07-07 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
EP2139526A4 (en) * 2007-04-03 2010-07-14 Trimeris Inc NEW FORMULATIONS TO RELEASE ANTIVIRAL PEPTIDE THERAPEUTICS
WO2011095989A2 (en) * 2010-02-04 2011-08-11 Matrix Laboratories Ltd An improved process for the preparation of enfuvirtide
EP2550290B1 (en) * 2010-03-24 2015-12-02 Medical Research Council Method of modifying a specific lysine
PL2571510T3 (pl) 2010-05-21 2019-03-29 Xl-Protein Gmbh Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania
CN104788548B (zh) * 2014-01-20 2018-06-05 中国人民解放军军事医学科学院毒物药物研究所 新型抗hiv感染多肽及其利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same

Also Published As

Publication number Publication date
EP1734994A1 (en) 2006-12-27
JP2007529522A (ja) 2007-10-25
WO2005089796A1 (en) 2005-09-29
CN1929860A (zh) 2007-03-14
CA2556032A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
IL177268A0 (en) Site -specific chemical modification of hiv gp41-derived peptides
EP1809259A4 (en) PHARMACEUTICAL PREPARATIONS FOR WHICH THE RISK OF ABUSE IS REDUCED
GB0428328D0 (en) Chemical process
AU2003284939A8 (en) Gas diffusion electrodes
GB0616875D0 (en) Micro chemical system
EP1859063A4 (en) REPLIKIN PEPTIDES AND USES THEREOF
IL178064A0 (en) Chemical process and new crystalline form
HU0500701D0 (en) Conductive-polymer electrode from multicomponent system and the use thereof
TWI366562B (en) Chemical process
GB0426057D0 (en) Chemical process
TWI346671B (en) Chemical composition and process
ZA200709605B (en) HIV vaccine
GB0403744D0 (en) Chemical process
EP1802332A4 (en) MODIFIED HIV-1 CREAM PROTEINS
GB0426059D0 (en) Chemical process
GB0426662D0 (en) Gas imager
GB0411687D0 (en) Peptide mass spectrometry
GB0428101D0 (en) Chemical Processes & Intermediates
GB0502301D0 (en) Gas reactor electrode connections
GB0411596D0 (en) Chemical process
EP1775579A4 (en) OXYGEN ELECTRODE
GB0413209D0 (en) Chemical composition
GB0408424D0 (en) Viral assay
GB0410818D0 (en) Chemical resistant ultramarine composition
GB0428103D0 (en) Chemical Process